Hammer et al. 1 examined 2817 subjects, including 1325 healthy subjects and patients with schizophrenia (1081), Parkinson disease (263) and affective disorders (148) for the presence of several immunoglobulin subtypes of antibodies against the NR1 subunit of the NMDA receptor (NMDAR). In this large-scale screening, they found that 10.5% of all subjects were seropositive. The authors conclude that schizophrenic individuals with a past or present history of blood-brain barrier (BBB) disturbance are more likely to have more pronounced neurological symptoms upon NMDAR antibody seropositivity. However, there is no data supporting this conclusion in any of the sections of the manuscript:
(1) The authors' conclusion was based on retrospective review of clinical information for possible neurotrauma at birth or thereafter in the patients and controls. Even assuming that there was neurotrauma (which in fact is not clearly demonstrated), the authors do not provide any evidence that it altered the integrity of the BBB. (2) In the experiments with cultured neurons the authors claim that decreased NMDAR immunostaining was visible with confocal microscopy after incubation with patients' antibodies for 20 min, 'subsequently placing the cells in pre-warmed growth medium for 15 min to allow internalization.' However, other than a graph, there is no data showing confocal microscopy pictures of the density of cell surface/synaptic NMDAR clusters before and after incubation with patients' antibodies. The findings are hard to explain given that studies by other investigators on antibody-mediated NMDAR internalization using patient samples with very high titer antibodies (for example, those with anti-NMDAR encephalitis) found no detectable internalization using confocal microscopy until~4 h after neuronal incubation, reaching a plateau at~24 h. 2, 3 (3) In contrast to the authors' suggestion, the mouse experiments do not provide supporting evidence to their interpretation of the patients' findings (point 1). For this, in the minimum, the authors should demonstrate that the systemic injection of patients' immunoglobulin G (IgG) reaches the brain of mice, binds to NMDAR and alters receptor levels and function.
In a clinical series by Steiner et al., 4 including 459 subjects (121 with schizophrenia, 70 major depression, 38 borderline personality disorder (BLPD) and 230 controls), none had IgG NR1 subtype antibodies (two positive cases had anti-NMDAR encephalitis)-a finding closely resembling the data of Hammer et al.
1 (18/2817, 13 patients, 5 controls; 0.6%). However, Steiner et al. 4 found that 9.9% patients with schizophrenia, 2.8% major depression, 0% BLPD and 0.4% controls had IgA or IgM antibodies, or IgG antibodies against NR1/NR2. The different incidence of NMDAR antibodies in healthy subjects of both series (137/1325 (10.8%) versus 1/230 (0.4%)) is surprising.
Overall, these findings cast doubt on the interpretation that Hammer et al. 1 made on their results, and show the difficulty that these authors and Steiner et al. 4 encountered in the interpretation of antibody testing (using only serum and a cell-based assay), a problem we recently reported. 5 In our opinion, the study of Hammer et al.
1 merely shows that NR1 IgG antibodies are extremely uncommon in patients with schizophrenia, and IgA or IgM antibodies are frequent among healthy individuals, lacking specificity.
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